Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

Our recent study demonstrated that a novel proteasome inhibitor NPI-0052 triggers apoptosis in multiple myeloma (MM) cells, and importantly, that is distinct from bortezomib (Velcade) in its chemical structure, effects on proteasome activities, and mechanisms of action. Here, we demonstrate that com...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chauhan, Dharminder, Singh, Ajita, Brahmandam, Mohan, Podar, Klaus, Hideshima, Teru, Richardson, Paul, Munshi, Nikhil, Palladino, Michael A., Anderson, Kenneth C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2008
Matèries:
Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2214767/
https://ncbi.nlm.nih.gov/pubmed/18006697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-08-105601
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars